DONNA

Closer to the FINISH

June 8th, 2015 | Posted In: Front Page Feature Old, Newsletter Articles, Research - Closer to the Finish

TapImmune, Inc. is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast cancer (Stages II-III) that had completed standard treatment (i.e. surgery, chemotherapy, and Herceptin™) at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine. Read more »

Leave a Reply

Be the First to Comment!

Notify of
wpDiscuz

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

Learn More about 26.2 with Donna Partners